Continuous glucose monitor

Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries

Retrieved on: 
Monday, April 17, 2023
CGM, Regulation of tobacco by the U.S. Food and Drug Administration, Insulin, Prevalence, Diabetes, FreeStyle, Abbott, Continuous glucose monitor, History, Medicare, Dizziness, Patient, Himawari (satellites), United, FDA, American Diabetes Association, NYSE, Safety, Pharmaceutical industry, Health insurance, Medical device

The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections

Key Points: 
  • The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections
    ABBOTT PARK, Ill., April 17, 2023 /PRNewswire/ -- More Medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using Abbott's (NYSE: ABT) FreeStyle Libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (CGM) in the United States.
  • "We've been focused on highlighting the tremendous benefits of continuous glucose monitoring to help people living with diabetes manage their care easily and pain-free.
  • Increasing access is a monumental step by Medicare to allow more people to have access to FreeStyle Libre so they can spend less time worrying and more time living healthier, better lives."
  • FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.

FDA Clears Reader for Abbott's FreeStyle Libre® 3 System

Retrieved on: 
Friday, April 14, 2023
Diabetes, FreeStyle, USB, Quality of life, Continuous glucose monitor, Medicare, GlySens ICGM, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Medical device

ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.

Key Points: 
  • ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.
  • "The FreeStyle 3 reader provides more choice to people living with diabetes to have access to lifesaving technology that is smaller and easier to use and comes without the high-cost burdens of other systems."
  • The reader uses a rechargeable lithium-ion battery, which is commonly found in many other electronic devices like mobile phones.
  • The user manual for the FreeStyle Libre 3 reader provides details on how to safely store, charge and use the device, including always using the Abbott-provided USB cable and power adapter.

U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems

Retrieved on: 
Monday, March 6, 2023
Insulin, NYSE, Tandem, Loop, Woman, Regulation of tobacco by the U.S. Food and Drug Administration, GlySens ICGM, FreeStyle, Food, Continuous glucose monitor, Diabetes, FDA, United, AID, CGM, Medical device, Dietary supplement, Fine chemical, Pharmaceutical industry, Pharmaceutical industry in Switzerland

AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.

Key Points: 
  • AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
  • Abbott is working with leading insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible.
  • The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors will be available in the U.S. later this year.
  • Over time, the modified sensors will replace the current FreeStyle Libre 2 and FreeStyle Libre 3 sensors available today in the U.S.

JQ Medical Appoints Matt Gallagher as President and Chief Executive Officer

Retrieved on: 
Monday, February 13, 2023
Diabetes, Medical Devices, Health, Pharmaceutical, Health Technology, Home medical equipment, Emergency medical services, JQ, Region, Falck (emergency services company), Health care, Continuous glucose monitor, Partner (business rank), Management

JQ Medical (“the Company”) announced that its board of directors has appointed 15-year Healthcare industry leader Matt Gallagher as its new chief executive officer, which Matt assumed effective February 6, 2023.

Key Points: 
  • JQ Medical (“the Company”) announced that its board of directors has appointed 15-year Healthcare industry leader Matt Gallagher as its new chief executive officer, which Matt assumed effective February 6, 2023.
  • Gallagher has also joined the JQ Medical board of directors upon assuming the role.
  • “I am thrilled to join and lead JQ Medical forward at this important time for the Company,” said Gallagher.
  • Prior to joining Breg, Matt served as the President and Chief Executive Officer of Falck USA, one of the largest private providers of emergency medical services in the United States.

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

Continuous Glucose Monitoring Fosters Blood Glucose Meters Industry Growth - Grand View Research, Inc.

Retrieved on: 
Wednesday, February 8, 2023
Benchmarking, CGM, Himawari (satellites), Traction, Insulin, Pan American Health Organization, Dexcom, Diagnosis, Innovation, Blood, POCT, Hypoglycemia, Diabetes, Blood sugar level, Red Data Book of the Russian Federation, POC, CDC, Intelligence, USD, Continuous glucose monitor, Disease, SAN, R, Self-management, COVID-19, PAHO, Abbott, Medical device, Retail, Pharmaceutical industry

An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.

Key Points: 
  • An unprecedented rise in the diabetic population has furthered the demand for technologies monitoring blood glucose.
  • Blood glucose monitoring devices have witnessed increased traction across developing and developed countries, mainly due to the need to stay on track with blood sugar goals.
  • The growth trajectory is primarily attributed to the trend for continuous glucose monitoring (CGM) technologies to track blood sugar levels.
  • Blood glucose meters manufacturers and suppliers are expected to cash in on the prevailing growth potentials to expand their penetration across yet-to-be-penetrated areas.

ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement

Retrieved on: 
Tuesday, December 27, 2022
Continuous glucose monitor, CES, VMX, CGM, Video game, EU

SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM.

Key Points: 
  • SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM.
  • The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market.
  • Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000.
  • “We will be exhibiting the GluCurve Pet CGM at CES January 5th-8th and VMX (Veterinary Meeting and Expo) January 14th-18th which should bolster awareness around the Company and GluCurve.

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Retrieved on: 
Wednesday, December 21, 2022
Consensus, FreeStyle, NYSE, AID, International Diabetes Center at Park Nicollet, Loop, Continuous glucose monitor, FX, JDRF, American Diabetes Association, Life, T1D, European Association for the Study of Diabetes, Disability, Multimedia, Nutritional immunology, Insulin, Medical device, Pharmaceutical industry, Diabetes

This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.

Key Points: 
  • This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.
  • Nearly five healthy years could be restored if they had access to devices that monitor glucose and automate insulin delivery.
  • "Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person's glucose levels and delivering the right insulin dosage, which can ultimately improve time in range.
  • In addition to partnering with Ypsomed and CamDiab, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

Retrieved on: 
Thursday, November 17, 2022
Adult, Chicago Innovation Awards, Monkeypox virus, FreeStyle, VR, PCR, Center for Food Safety and Applied Nutrition, Federal Food, Drug, and Cosmetic Act, EUA, Infection, COVID-19, CTA, Chronic pain, Ageing, Safety, FDA, Consumer Technology Association, NYSE, Severe acute respiratory syndrome coronavirus 2, Patient, Artificial intelligence, Consumer Electronics Show, Virus, Diabetes, Life, The Economist, Diagnosis, Engineering, Protein, Continuous glucose monitor, Digital health, Comparison, CES, Laboratory, Medical device, Consumer electronics, Vaccine, Pharmaceutical industry, Orthopoxvirus

Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:

Key Points: 
  • Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:
    Aveir VR Leadless Pacemaker Theworld's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable.
  • The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products.
  • Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years.
  • In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation.

Diabetes Awareness Month highlights the importance of regular eye care as vision loss prevention: Canadian Ophthalmological Society

Retrieved on: 
Tuesday, November 8, 2022
Diagnosis, DR, Diabetes, American Ophthalmological Society, Probability, Canadian Medical Association, Ophthalmology, Public Health Agency of Canada, Eye, Ageing, Association, Risk, Government, Public Health Agency, Physician, COS, Retina, Disease, Diabetic retinopathy, Leger, CMA, Time, Royal college, Health policy, Severe cognitive impairment, Gaps, Education, Cholesterol, Continuous glucose monitor, Partnership, Prediabetes, Professional development, RCPSC, Royal College of Physicians and Surgeons of Canada, Eye disease, Surgeon, Canadian Association of Optometrists, CPD, Awareness, Optometry, Pharmaceutical industry, Health insurance

TORONTO, Nov. 8, 2022 /CNW/ - November marks Diabetes Awareness Month and to help educate Canadians, the Canadian Ophthalmological Society (COS) wants to remind Canadians of the various complications that are associated with diabetes, specifically diabetic retinopathy (DR), an eye disease that can lead to vision loss.

Key Points: 
  • TORONTO, Nov. 8, 2022 /CNW/ - November marks Diabetes Awareness Month and to help educate Canadians, the Canadian Ophthalmological Society (COS) wants to remind Canadians of the various complications that are associated with diabetes, specifically diabetic retinopathy (DR), an eye disease that can lead to vision loss.
  • The recent national survey conducted by the COS, in partnership with the Canadian Association of Optometrists, identified gaps in the vision health system to help guide future interventions and address eye health issues across the country.
  • The implementation of the national strategy for eye care would allow for more education and awareness of DR and other various eye diseases.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.